The observed dependency on CD8+ cells of nivolumab treatment is in line with recent publications, which revealed the importance of CD8+ TIL in therapy response on ICI in several tumors such as melanoma (28) and renal carcinoma (29). This evidence concerns the gene CD8A and renal carcinoma.